Precision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancer

Nature Reviews Cancer

Volumn 17, Issue 3, 2017, Pages 199-204

  Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOMARKER SIGNATURE; UNCLASSIFIED DRUG; TUMOR MARKER;

BIOINFORMATICS; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENOMICS; HUMAN; MALIGNANT NEOPLASM; MEDICAL DOCUMENTATION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; BIOLOGY; BLOOD; EARLY CANCER DIAGNOSIS; NEOPLASMS;

BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; EARLY DETECTION OF CANCER; GENOMICS; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 85011036342     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.153     Document Type: Review

References (74)

1. World Health Organization. Cancer control: early detection: WHO guide for effective programmes. WHO http://www.who.int/cancer/publications/cancer control.detection/en/ (2007).
2. Shimizu, Y., Yasui, K., Matsueda, K., Yanagisawa, A., & Yamao, K. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J. Gastroenterol. Hepatol. 20, 1591-1594 (2005).
3. Brennan, D. J., et al. Antibody-based proteomics: fast-Tracking molecular diagnostics in oncology. Nat. Rev. Cancer 10, 605-617 (2010).
4. Neagu, M., Constantin, C., Tanase, C., & Boda, D. Patented biomarker panels in early detection of cancer. Recent Pat. Biomark. 1, 10-24 (2011).
5. Vlahou, A. Network views for personalized medicine. Proteomics Clin. Appl. 7, 384-387 (2013).
6. Franzi, M., Bhat, A., & Latosinska, A. Clinical proteomic biomarkers: relevant issues on study design and technical considerations in biomarker development. Clin. Transl Med. 3, 7-22 (2014).
7. Polanski, M., & Anderson, N. L. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 2, 1-48 (2007).
8. Füzey, A. K., Levin, J., Chan, M. M., & Chan, D. W. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 10, 13-27 (2013).
9. Menon, U., et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-Threshold rule in the United Kingdom Collaborative Trial of Ovarian cancer screening. J. Clin. Oncol. 33, 2062-2075 (2015).
10. Pavlou, M. P., Diamandis, E. P., & Blasutig, I. M. The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 59, 147-157 (2013).
11. Smart, A. A multi-dimensional model of clinical utility. Int. J. Qual. Health Care 18, 377-382 (2006).
12. Zhang, Z., & Chan, D. W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers Prev. 19, 2995-2299 (2010).
13. Kiyonami, R., et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol. Cell. Proteomics 10, M110.002931 (2011).
14. Tighe, P. J., Ryder, R. R., Todd, I., & Fairclough, L. C. ELISA in the multiplexed era: potentials and pitfalls. Proteomics Clin. Appl. 9, 406-422 (2015).
15. Haab, B. B. Applications of antibody array platforms. Curr. Opin. Biotechnol. 4, 415-421 (2006).
16. Borrebaeck, C. A. K., & Wingren, C. Design of high-density antibody microarrays for disease proteomics: key technological issues. J. Proteomics 72, 928-935 (2009).
17. Bradbury, A., & Pluckthun, A. Reproducability: standardized antibodies used in research. Nature 518, 27-29 (2015).
18. Alhamdani, M. S. S., Schröder, C., & Hoheisel, J. D. Oncoproteomic profiling with antibody microarrays. Genome Med. 1, 1-7 (2009).
19. Liotta, L. A., et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317-325 (2003).
20. Borrebaeck, C. A. K., & Wingren, C. Recombinant antibodies for the generation of antibody arrays. Methods Mol. Biol. 785, 247-262 (2011).
21. Yu, X., Schneiderhan-Marra, N., & Joos, T. O. Protein microarray for personalized medicine. Clin. Chem. 56, 376-387 (2010).
22. Ellmark, P., et al. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol. Cell. Proteomics 5, 1638-1646 (2006).
23. Carlsson, A., et al. Serum protein profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 44, 472-480 (2008).
24. Shao, C., et al. Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls. Proteomics Clin. Appl. 3, 923-931 (2009).
25. Chapman, C. J., et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin. Cancer Res. 17, 1474-1480 (2011).
26. Sonntag, J., et al. Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer. Transl Proteomics 2, 52-59 (2014).
27. Brand, R. E., et al. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17, 805-816 (2011).
28. Sauer, G., et al. Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays. J. Cancer Res. Clin. Oncol. 137, 1175-1184 (2011).
29. Nolen, B. M., et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS ONE 9, e94928 (2014).
30. Rosskopf, S., et al. The pre-Analytical processing of blood samples for detecting niomarkers on protein microarrays. J. Immunol. Methods 418, 39-51 (2015).
31. Rai, A. J., et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277 (2005).
32. Alonzo, T. A., Pepe, M. S.& Moskowitz, C. S. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat. Med. 21, 835-852 (2002).
33. Melo, S. A., et al. Glypican 1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177-182 (2015).
34. Borrebaeck, C. A. K. Viewpoints in clinical proteomics. Proteomics Clin. Appl. 6, 343 (2012).
35. Benjamini, Y., & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289-300 (1995).
36. Carlsson, A., et al. Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc. Natl Acad. Sci. USA 108, 14252-14257 (2011).
37. Kullback, S., & Leibler, R. A. On information and sufficiency. Ann. Math. Stat. 22, 79-86 (1951).
38. Hansh, S. M., Pitteri, S. J., & Faca, V. M. Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579 (2008).
39. Zethelius, B., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107-2116 (2008).
40. Van 't Veer, L. J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
41. Van de Vijver, M. J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
42. Cusumano, P. G., et al. European inter-institutional impact study of MammaPrint. Breast 23, 423-428 (2014).
43. Sparano, J. A., et al. Prospective validation of a 21 gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005-2014 (2015).
44. Olsson, E., et al. Serial monitoring of circulation tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 7, 1034-1047 (2015).
45. Moyer, V. A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Int. Med. 157, 120-134 (2012).
46. Sartori, D. A., & Chan, D. W. Biomarkers in prostate cancer: what's new? Curr. Opin. Oncol. 26, 259-264 (2014).
47. Heijnsdijk, E. A., Denham, D., & de Koning, H. J. The cost-effectivness of prostate cancer detection with the use of prostate health index. Value Health 19, 153-157 (2016).
48. Grönberg, H., et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 16, 1667-1676 (2015).
49. Schully, S. D., et al. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J. Natl Cancer Inst. 107, djv012 (2015).
50. Ransohoff, D. F. Proteomics research to discover markers: what can we learn from Netflix? Clin. Chem. 56, 172-176 (2010).
51. Zhang, Z., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
52. Bast, R. C., et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337 (1981).
53. Bristow, R. E., et al. Ovarian malignancy risk classification of adnexal mass using a multivariate index assay. Gynecol. Oncol. 128, 252-259 (2013).
54. Coleman, R. L., et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am. J. Obstet. Gynecol. 82, 1-11 (2016).
55. Anderson, N. L., & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 11, 845-867 (2002).
56. Makarov, A., Denisov, E., Lange, O., & Horning, S. Dynamic range of mass accuracy in LTQ Orbitrap hybrid mass spectrometer. J. Am. Mass Spectrom. 17, 977-982 (2006).
57. Parker, C. E., & Borchers, C. H. Mass spectrometry based biomarker discovery, verification, and validation-quality assurance and control of protein biomarker assays. Mol. Oncol. 8, 840-858 (2014).
58. Abbatiello, S. E., et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol. Cell. Proteomics 14, 2357-2374 (2015).
59. Razavi, M., Anderson, N. L., Yip, R., Pope, M. E., & Pearson, T. W. Multiplexed longitudinal measurements of protein biomarkers in DBS using an automated SISCAPA workflow. Bioanalysis 8, 1597-1160 (2016).
60. Waldemarson, S., et al. Proteomic analysis of breast tumors confirms the mRNA intrinstic molecular subtypes using different classifiers: a large-scale analysis using fresh frozen tissue samples. Breast Cancer Res. 18, 69 (2016).
61. Nordström, M., et al. Identification of plasma protein profiles associated with risk groups of prostate cancer patients. Proteomics Clin. Appl. 8, 951-962 (2014).
62. Lee, M. S., et al. Prognostic significance of CREB-binding protein and CD81 expression in primary high grade non-muscular invasive bladder cancer: identification of novel biomarkers for bladder cancer using antibody microarray. PLoS ONE 10, e0125405 (2015).
63. Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S., & Swisher, E. Cancer biomarkers: a systemic approach. Nat. Biotechnol. 24, 905-908 (2006).
64. Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. Pancreatic cancer. Lancet 388, 73-85 (2016).
65. Ghatnekar, O., et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int. J. Cancer 133, 2392-2397 (2013).
66. Mirus, J. E., et al. Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/ threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease. Mol. Cell. Proteomics 13, 3484-3496 (2014).
67. Mirus, J. E. Cross-species antibody microarray interrogation identifies a 3 protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin. Cancer Res. 21, 1764-1771 (2015).
68. Wingren, C., et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 72, 2481-2490 (2012).
69. Sandström, A., et al. Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease-Associated biomarker signatures. Proteomics Clin. Appl. 6, 486-496 (2012).
70. Gerdtsson, A. S., et al. A multicenter trial defining a serum protein signature associated with pancreatic ductal adenocarcinoma. Int. J. Proteomics 2015, 587250 (2015).
71. Wu, T. C., Shao, Y. F., Shan, Y., Wu, J. X., & Zhao, P. Surgical effect of malignant tumor of body and tail of the pancreas: compare with pancreatic head cancer. Chin. J. Surg. 45, 30-33 (2007).
72. Gerdsson, A. S., et al. Plasma protein profiling in a stage defined pancreatic cancer cohort-implications for early diagnosis. Mol. Onc. 10, 1305-1316 (2016).
73. Mansfield, E. A. FDA perspective on companion diagnostics: an evolving paradigm. Clin. Cancer Res. 20, 1453-1457 (2014).
74. Dinakarpandian, D. in Big Data Analysis for Bioinformatics and Biomedical Discoveries (ed. Ye, S. Q.) 249-264 (CRC Press, 2016).